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Background: Rapid conversion of atrial fibrillation (AF) to sinus rhythm may be achieved by the administration of
class IA, IC and III antiarrhythmic drugs or vernakalant hydrochloride. However, that treatment may be related to
potential pro-arrhythmia, lack of efficacy or the exceptionally high cost of a compound used. Antazoline is a first
generation antihistaminic agent with chinidin-like properties. When administered intravenously, antazoline exerts a
strong antiarrhythmic effect on supraventricular arrhythmia, especially on AF, facilitating rapid conversion to sinus
rhythm. Despite a relative lack of published data antazoline has been marketed in Poland and widely used in
cardiology wards and emergency rooms for many years due to its efficacy, safety and rapid onset of action within
minutes of administration.
Methods/design: A randomized, double blind, placebo-controlled, superiority clinical trial was designed to assess
clinical efficacy of antazoline in rapid conversion of AF to sinus rhythm. Eligible patients will present AF lasting less
than 43 hours, will be in stable cardio-pulmonary condition and will have no prior history of advanced heart failure
or significant valvular disease. Long-term antiarrhythmic therapy is not considered an exclusion criterion. Subjects
who fulfill selection criteria will be randomly assigned to receive intravenously either antazoline or placebo in
divided doses and observed for 1.5 hours after conversion to sinus rhythm or after the last i.v. bolus. Primary end
point will be the conversion of AF to sinus rhythm confirmed in an electrocardiogram (ECG) during the observation
period. Secondary end points will be comprised of time to conversion and return of AF during the observation
period. Special consideration will be given to the observation of any adverse events. A sample size of 80 patients
was calculated based on the following assumptions: two-tailed test, a type I error of 0.01, a power of 90%, efficacy
of placebo 5%, efficacy of antazoline 50% and 20% drop-out rate to fulfill the criteria of intention-to-treat analysis.
Due to the presumed lack of statistical power, the secondary end points and safety endpoints will be considered
exploratory.
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Atrial fibrillation (AF) is considered to be not only a
medical but also a social problem. It is related to the ele-
vated risk of thrombo-embolic events with a stroke
being the most important and it adversely affects life ex-
pectancy and quality. The cornerstone of AF therapy is a
long-term antithrombotic treatment followed by ad-
equate rhythm or rate control [1,2]. The pharmaco-
logical cardioversion (CV) of AF to sinus rhythm (SR)
may be achieved by administration of class IA, IC and
III antiarrhythmic drugs: flecainide, ibutilide, dofetilide,
propafenone or amiodarone [1,2]. Beta-adrenergic block-
ing agents are not considered suitable for pharmaco-
logical CV due to their low or lack of efficacy. Another
drug recently introduced for rapid CV of AF is vernaka-
lant [3-6]. Pharmacological CV may be related to poten-
tial pro arrhythmia, lack of efficacy or exceptionally high
cost of a compound used.
So far there is no significant evidence of superiority of
either rate or rhythm control strategies in terms of mor-
tality, severe AF complication rates, worsening of heart
failure quality of life of patients with AF. A hypothesis
that deleterious effects of antiarrhythmic drugs may have
offset the benefits of SR in those patients is seriously
considered. Therefore a decision of SR restoration and
maintenance for a long time should be patient-tailored
and based on the individual patient’s history, symptoms
and preferences [1].
Antazoline is a first generation antihistaminic agent
with chinidine-like and anticholinergic properties. Anta-
zoline prolongs action potential duration and lowers its
amplitude, prolongs phase 0 duration, reduces phase 4
of resting potential and reduces excitability of cardiac
tissue. Clinically, antazoline lowers the velocity of intraa-
trial conduction, prolongs the atrial refraction period
and may improve atrioventricular conduction allowing
fast ventricular response to supraventricular arrhyth-
mias. The half-life of antazoline is considered to be
about three hours with antiarrhythmic efficacy expiring
after about one hour [7-9].
There are no widely known sound randomized clin-
ical studies conducted to evaluate the antiarrhythmic
effect of antazoline. Published studies were mainly
single-arm clinical trials with no control group or a
different series of cases where antazoline was adminis-
tered either orally or intravenously in different doses
and in different arrhythmias. These studies suggested
high efficacy of antazoline in rapid conversion of AF
to SR if administered intravenously up to the cumu-
lated dose of 350 mg. Most adverse effects were
observed after cumulated doses exceeding 250 mg and
they were mainly comprised of mild hypotension, hot
flushes and mild tachycardia. Antazoline can unmask
the underlying sick sinus syndrome or atrio-ventricularblock [7,8,10-27]. Moreover, antazoline has been used
in clinical practice in Poland for many years due to its
efficacy, safety and rapid onset of action within min-
utes of administration. According to the Summary of
Product Characteristics, antazoline is indicated in the
treatment of paroxysmal supraventricular tachyarrhyth-
mias including AF and should be administered intra-
venously in a cumulative dose of 100 to 300 mg
during 3 to 10 minutes under strict monitoring of
ECG and arterial blood pressure and interrupted after
conversion to SR.
The aim of this randomized, double blind, placebo-
controlled, superiority clinical trial is to assess clinical
efficacy of antazoline in rapid conversion of atrial
fibrillation to sinus rhythm in patients with paroxysmal
atrial fibrillation without significant valvular disease or
advanced heart failure.
Methods/design
The study protocol was approved by the local ethics
committee and is in full compliance with the Declaration
of Helsinki.
Participants
All patients with AF lasting less than 43 hours reporting
to the emergency room (ER) or clinical ward of our cen-
ter will be considered for inclusion.
Inclusion criteria
– Written informed consent for participating in the
study and written standard version of informed
consent for cardioversion accepted at the Institute of
Cardiology, Warsaw, Poland
– Age 40 to 75 years
– Potassium blood concentration over 3.5 mmol/l
– Stable cardio-pulmonary state on enrollment
– In case of unclear history of heart failure or
suspicion of left ventricle damage echocardiography
is indicated prior to enrollment
– A long-term antiarrhythmic drug therapy is allowed
Exclusion criteria
– Lack of written informed consent
– Allergy to antazoline
– AF related to significant valvular disease
– Clinically significant heart failure or ejection fraction
<55%
– Diastolic blood pressure (BP) <100 mmHg
– History of significant bradyarrhythmia not treated
with permanent pacemaker
– QT prolongation over 440 ms or QTc (Bazett’s
formula) over the population norm
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– Advanced liver or kidney failure
– Acute coronary syndrome, coronary artery by-pass
graft, stroke or transient ischemic attack within
30 days before enrollment
– Preexcitation in ECG not treated by radiofrequency
ablation of accessory pathway
– Signs and symptoms of ischemia related to AF
– An investigational drug used within 30 days before
enrollment
– Pregnancy or breast feeding
Time window
The AnPAF Study is designed both for symptomatic and
asymptomatic patients.
In symptomatic patients the self-reported onset of
symptoms is considered when determining the time of
AF episode. In symptomatic patients on long term anti-
arrhythmics or oral anticoagulants the self-reported
onset of symptoms of a recent episode of AF is consid-
ered when determining the inclusion criteria.
In asymptomatic patients a medical documentation of
SR within the last 43 hours must be available to enroll
the patient (for example ECG strip).
In order to ensure patients’ safety in all ambiguous or




Apart from the assigned drug the treatment of both
groups will not differ at any time during the study.
Any patient fulfilling the inclusion criteria will be
prepared to pharmacological CV in a standard way
comprising the standard baseline 12-lead ECG, con-
tinuous ECG monitoring, periodic noninvasive blood
pressure monitoring (BP) and iv line. The study drug
or placebo will be administered intravenously in
boluses by a nurse under supervision of the enrolling
physician, both blinded to patient assignment. Both
substances will be prepared in syringes by the study
nurse unblinded to patient assignment. After adminis-
tration the patient will be observed for 1.5 hour after
the last dose with exit ECG and BP measure taken at
the end of observation. Further treatment of the pa-
tient depends on the clinical state and follows current
clinical guidelines.
Study group
Patients assigned to the antazoline group will be admi-
nistered antazoline in boluses of 50 mg diluted to
10 cm3 every five minutes up to a cumulative dose of
250 mg or conversion of AF to SR. Drug administration
will also be stopped in case of an adverse event (seeOutcomes section) or conversion of AF to a different
supraventricular arrhythmia. BP will be measured before
every injection.
Control group
Patients assigned to the control group will be adminis-
tered 0.9% saline in boluses of 10 cm3 every five min-
utes up to a cumulative volume of 50 cm3, conversion
of AF to SR or in case of an adverse event (see Out-
comes section) or conversion of AF to a different
supraventricular arrhythmia. BP will be measured be-
fore every injection.
Objectives
The purpose of the study is to assess clinical efficacy of
antazoline in rapid conversion of AF to SR in patients
with paroxysmal atrial fibrillation without significant
valvular disease or advanced heart failure. Due to a pre-
sumed lack of statistical power, secondary end points
and safety analysis will be considered exploratory.
Outcomes
All clinical outcomes will be assessed by the enrolling
physician and later adjudicated by an experienced cardi-
ologist both blinded to patients assignment.
All safety outcomes will be assessed by the enrolling
physician blinded to patient’s assignment. In order to
provide maximum safety for the patient, a physician
unblinded to patent’s assignment but not involved in the
clinical outcomes assessment will be available at the
study site at all times.
Primary outcome: conversion of AF to SR confirmed in
standard 12-lead ECG during the observation period
Secondary end points: time to conversion; return of AF
during observation period; serious adverse event
defined as every adverse event requiring hospitalization
or prolonged observation
Safety endpoints
– BP <90 mmHg
– Disturbances of atrio-ventricular conduction
– Sustained supraventricular arrhythmia other than
AF







– Prolongation of QTc (Bazett’s formula) in
comparison to baseline (in ms)
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Randomization will be provided by the independent sta-
tistician using SAS.9.2 software, SAS Institute Inc., Cary,
NC, U.S.A.. Permuted block randomization will be used
with a block size (AB, BA) not known by the investiga-
tors. After eligible patients give informed consent a spe-
cific unique identifier will be assigned to the patients.
Use of this randomization process ensures proper trial
enrollment and promptly provides the statistician with
the basic patients enrollment information needed to
monitor enrollment performance.
Allocation concealment
A Random allocation sequence will be implemented
using numbered sealed envelopes opened after inclusion
of the patient for the study.
Implementation
After inclusion of the patient the study the nurse will
open the numbered envelope and prepare five 10 cm3
syringes with study drug or placebo according to
randomization and pass them to the enrolling physician
and nurse who will administer the drug.
Blinding
The study will be conducted in double-blind fashion.
The patient, enrolling physician, nurse who administer-
ing the drug, and clinician reviewing the clinical out-
comes will all be blinded to the treatment. The
statistician, study nurse who prepares the syringes and




The clinical efficacy of antazoline was assumed using
data derived from Srzednicki et al. 1990 [8], the most
credible publication available. Assumption of 50% effi-
cacy in AF conversion is conservative, since the authors
reported efficacy over 70% in doses not exceeding 250
mg of antazoline. Assumption of 5% efficacy of placebo
was derived from studies over vernakalant [3-6]. Using a
two-tailed test, a type I error of 0.01, a power of 90%
and a 20% drop-out rate to fulfill the criteria of
intention-to-treat analysis, we calculated that we need
80 patients, 40 in each group, to show the superiority of
antazoline over placebo.
Data management
During the study, the investigator will regularly enter in-
formation into case report forms (CRFs). Database man-
agement and quality control for this study will be the
responsibility of the Department of Biostatistics (this is
an independent statistician). Structured data elementsfrom the CRFs will be entered into the database and
reviewed using double data entry for verification. Infor-
mation entered into the database will be systematically
checked and obvious errors will be corrected. Omissions
or questions will be returned to the investigator for
resolutions.
Statistical analysis
All analyses will be conducted using SAS software (ver-
sion 9.2., SAS Institute Inc., Cary, NC, USA. The
Kolmgorov-Smirnov test will be used to check for nor-
mal distribution of continuous data. Normally distribu-
ted continuous data will be presented in terms of mean
± standard deviation. They will be compared across two
groups with the two-sided unpaired t-test or Cochran-
Cox test when there is heterogeneity of variance (evalu-
ated by the F-Snedocor test). Non-normally distributed
continuous data will be reported in terms of percentiles
(for example, median and inter-quartile range) and will
be compared across two groups by Wilcoxon rank-sum
test. Student’s paired t- or Wilcoxon’s test will be used
as appropriate to compare continuous variable differ-
ences between baseline and the end of the observation
period. Categorical variables will be summarized in
terms of frequencies and percentages. A comparison be-
tween them will be performed by Pearson’s χ2 test with
continuity correction or Fisher’s exact test, if the
expected cell count will be less than 5. The probability of
return to SR (by the time from AF) by the treatment group
will be graphically displayed according to the method of
Kaplan–Meier, with comparison of cumulative events by
the log-rank test. Multivariate analysis will be carried out
using Cox proportional hazards regression modeling. All
hypotheses will be two-tailed with a 0.05 type I error.
Trial status
We are in the recruiting phase.
Abbreviations
AF: atrial fibrillation; BP: blood pressure; CRFs: case report forms;
CV: cardioversion; ECG: electrocardiogram; ER: emergency room;
QTc: corrected QT interval; SR: sinus rhythm.
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